GlobeNewswire Inc.·Apr 7·NaPharming Group Boosts Investor Outreach Amid Leniolisib CHMP Approval WinPharming Group schedules April 2026 investor conferences following positive CHMP opinion for Joenja® leniolisib in APDS treatment. PHARinvestor conferencebiopharmaceutical
GlobeNewswire Inc.·Feb 24·Pomerantz LlpPomerantz Initiates Securities Investigation into Pharming Group Following FDA RejectionPomerantz Law Firm investigates Pharming Group after FDA rejects pediatric drug application, causing 17% stock decline. Inquiry focuses on whether regulatory risks were adequately disclosed to investors. PHARsecurities fraudclass action lawsuit